NO962187L - Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav - Google Patents

Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav

Info

Publication number
NO962187L
NO962187L NO962187A NO962187A NO962187L NO 962187 L NO962187 L NO 962187L NO 962187 A NO962187 A NO 962187A NO 962187 A NO962187 A NO 962187A NO 962187 L NO962187 L NO 962187L
Authority
NO
Norway
Prior art keywords
compositions
methods
inhibit apoptosis
purifying
extracts
Prior art date
Application number
NO962187A
Other languages
English (en)
Other versions
NO962187D0 (no
Inventor
Ian Cyril Bathurst
John D Bradley
L David Tomei
Philip J Barr
Original Assignee
Lxr Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lxr Biotechnology Inc filed Critical Lxr Biotechnology Inc
Publication of NO962187D0 publication Critical patent/NO962187D0/no
Publication of NO962187L publication Critical patent/NO962187L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

Fremgangsmåter for oppnåelse av plante-avledede delipiderte ekstrakter som inhiberer apoptose, ekstrakter oppnådd, sammensetninger inneholdende nevnte ekstrakter og fremgangsmåter for anvendelse av nevnte sammensetninger er beskrevet. Figuren er en bar graf som illustrerer en lavere forekomst av diaré i rotter behandlet med metotreksat og foret med en diett av sammensetningene sammenlignet med kontrollene.
NO962187A 1993-11-30 1996-05-29 Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav NO962187L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15898093A 1993-11-30 1993-11-30
US08/320,155 US5759548A (en) 1993-11-30 1994-10-07 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
PCT/US1994/013649 WO1995015173A1 (en) 1993-11-30 1994-11-30 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Publications (2)

Publication Number Publication Date
NO962187D0 NO962187D0 (no) 1996-05-29
NO962187L true NO962187L (no) 1996-07-30

Family

ID=26855549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962187A NO962187L (no) 1993-11-30 1996-05-29 Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav

Country Status (14)

Country Link
US (8) US5759548A (no)
EP (1) EP0732930B1 (no)
JP (2) JPH11501284A (no)
KR (1) KR960706350A (no)
CN (1) CN1140998A (no)
AT (1) ATE302015T1 (no)
AU (1) AU678090B2 (no)
CA (1) CA2177825A1 (no)
DE (1) DE69434459T2 (no)
FI (1) FI962246L (no)
HU (1) HUT76096A (no)
NO (1) NO962187L (no)
NZ (1) NZ277403A (no)
WO (1) WO1995015173A1 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6782494A (en) * 1993-04-30 1994-11-21 Lxr Biotechnology Inc. Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5620888A (en) * 1994-12-29 1997-04-15 Lxr Biotechnology, Inc. Cell strains for use in identifying potentially therapeutically effective agents
CN1200036A (zh) * 1995-09-14 1998-11-25 Lxr生物技术有限公司 含有磷脂混合物并具有抗细胞程序死亡活性的组合物
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
AU2814897A (en) * 1996-04-25 1997-11-12 T Cell Sciences, Inc. Method of isolating regulators of t cell activation
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
EP0932678B2 (en) 1996-09-24 2010-03-10 Genentech, Inc. A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US20070299005A1 (en) 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
IL119535A (en) * 1996-10-31 2001-01-11 Chajuss Daniel Soy molasses and modified soy molasses for topical application
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
US6321909B1 (en) 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
CA2301921A1 (en) * 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
EP0911634A1 (en) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmaceutical uses of CDK-2 regulators
EP1069895A4 (en) * 1998-03-18 2002-07-31 Lxr Biotechnology Inc COMPOSITIONS CONTAINING LYSOPHOSPHATIDE ACIDS THAT INHIBIT APOPTOSIS AND USES THEREOF
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US5869063A (en) * 1998-06-29 1999-02-09 Protease Sciences, Inc. Dermatological and cosmetic compositions containing marama bean extract
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6413556B1 (en) * 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6355618B1 (en) * 1999-04-09 2002-03-12 Cytovia, Inc. Caspase inhibitors and the use thereof
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
US6500810B2 (en) * 1999-12-14 2002-12-31 Sky High, Llc Method of regulating expression of adhesion molecules on circulating leukocytes
US20070048726A1 (en) * 2000-01-14 2007-03-01 Biolife Solutions, Inc. Methods and Compositions for the Control of Molecular-Based Cell Death During Preservation of Cells, Tissues or Organs in a Gel-Like State
US20060063738A1 (en) * 2000-02-28 2006-03-23 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
US6861077B1 (en) * 2000-03-17 2005-03-01 L'oreal S.A. Use of plant extracts in a cosmetic composition to protect keratinous fibers
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use
CA2458068A1 (en) * 2001-08-20 2003-02-27 Tatton Technologies, Llc. Methods and compositions for treating apoptosis associated disorders
US20030077264A1 (en) * 2001-09-20 2003-04-24 Goodrich Laura L. Antimicrobial blood treatment using allicin and related compounds
ES2348230T3 (es) * 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2386310B1 (en) * 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
EP1398019A1 (de) 2002-09-13 2004-03-17 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions
WO2004024964A2 (en) * 2002-09-13 2004-03-25 Olin Corporation Age-hardening copper-base alloy and processing
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US7829277B2 (en) 2004-03-01 2010-11-09 The Regents Of The University Of California Methods for identifying compounds that suppress chemically-induced carcinogenesis
US20060035827A1 (en) * 2004-06-24 2006-02-16 Green Gary M Compositions and methods for the treatment or prevention of gallbladder disease
US7691417B2 (en) 2004-09-02 2010-04-06 Clemson University Research Foundation Tumor and mutation suppressing plant extract
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US8187643B2 (en) * 2007-03-28 2012-05-29 Greg Steininger, legal representative Shampoo formulation for treatment of hair loss and method of use
WO2010005560A2 (en) * 2008-07-07 2010-01-14 Woods Hole Oceanographic Institution Methods for obtaining bioactive compounds from phytoplankton
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
WO2011057132A1 (en) * 2009-11-05 2011-05-12 Woods Hole Oceanographic Institution Methods for obtaining bioactive compounds from phytoplankton
US8927009B2 (en) * 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) * 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
JPS54117034A (en) * 1978-02-28 1979-09-11 Nippon Shoji Kk Treating agent for consciousness and perception motion disorder
ATE73345T1 (de) * 1984-10-19 1992-03-15 Chiron Corp Anregung zur heilung einer wunde mittels menschlichen hautwachstumsfaktors hergestellt durch rekombinant-dns.
US4793996A (en) * 1984-11-14 1988-12-27 Ann R. Kennedy Method of making soybean extract inhibitor
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
JPS62155082A (ja) * 1985-12-27 1987-07-10 Karupisu Shokuhin Kogyo Kk ビフイズス菌増殖物質の製造法
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
JPS6351335A (ja) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd 肥満細胞脱顆粒抑制剤
US4746652A (en) * 1986-11-18 1988-05-24 Wake Forest University Method of inducing diuresis with lysophospholipids
US4959310A (en) * 1987-09-28 1990-09-25 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to soybean kunitz trypsin inhibitor and immunoassay methods
US5053327A (en) * 1988-09-20 1991-10-01 The United States Of America As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies to bowman-birk inhibitor and immunoassay methods
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JP2809429B2 (ja) * 1989-05-26 1998-10-08 湧永製薬株式会社 制ガン剤ならびに制ガン剤として有用な新規複素環化合物またはそれらの塩
US5376373A (en) * 1990-09-06 1994-12-27 Trustees Of The University Of Pennsylvania Method of inhibiting radiation induced weight and hair loss
US5217717A (en) * 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
US5340568A (en) * 1992-07-01 1994-08-23 The Procter & Gamble Company Topical composition and method containing deoxy and halo derivatives of lysophosphatidic acids for regulating skin wrinkles
US5636187A (en) 1992-12-11 1997-06-03 Canon Kabushiki Kaisha Magnetooptical recording apparatus and magnetooptical recording method for canceling leakage magnetic fields associated with a recording medium and devices ancillary to the recording medium
US5277917A (en) * 1993-04-02 1994-01-11 Allelix Biopharmaceuticals Inc. Ovarian cancer ascites factor, in isolated form
AU6782494A (en) * 1993-04-30 1994-11-21 Lxr Biotechnology Inc. Methods of identifying potentially therapeutically effective agents and cell strains for use therein
NZ248603A (en) * 1993-05-28 1994-12-22 Abbott Lab Nutritional product for enteral nutritional support of hiv victims comprising proteins and fat
US5330972A (en) * 1993-05-28 1994-07-19 Abbott Laboratories Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof

Also Published As

Publication number Publication date
CA2177825A1 (en) 1995-06-08
JP2007084573A (ja) 2007-04-05
ATE302015T1 (de) 2005-09-15
NO962187D0 (no) 1996-05-29
EP0732930A1 (en) 1996-09-25
CN1140998A (zh) 1997-01-22
HUT76096A (en) 1997-06-30
US5624672A (en) 1997-04-29
AU678090B2 (en) 1997-05-15
US6656729B2 (en) 2003-12-02
DE69434459T2 (de) 2006-04-06
US20020110608A1 (en) 2002-08-15
US5759548A (en) 1998-06-02
AU1261295A (en) 1995-06-19
DE69434459D1 (de) 2005-09-22
FI962246A0 (fi) 1996-05-29
JPH11501284A (ja) 1999-02-02
FI962246A7 (fi) 1996-07-22
US5567425A (en) 1996-10-22
NZ277403A (en) 1998-03-25
US6306398B1 (en) 2001-10-23
US5635187A (en) 1997-06-03
FI962246L (fi) 1996-07-22
US5635186A (en) 1997-06-03
EP0732930A4 (en) 1997-10-29
KR960706350A (ko) 1996-12-09
US5620885A (en) 1997-04-15
EP0732930B1 (en) 2005-08-17
HU9601449D0 (en) 1996-07-29
WO1995015173A1 (en) 1995-06-08

Similar Documents

Publication Publication Date Title
NO962187L (no) Sammensetninger som inhiberer apoptose, fremgangsmåter for rensing av sammensetningene og anvendelse derav
ES2147551T3 (es) Procedimiento para transformar plantas monocotiledoneas.
ATE172849T1 (de) Behandlung von nahrungsmitteln durch infrarotstrahlung
ATE127691T1 (de) Verwendung von vitamin-d-analoga zur behandlung von akne.
FI962445A7 (fi) Paroksetiinitabletteja ja menetelmä niiden valmistamiseksi
NO893697L (no) Flytendegjoeringsprosess for naturgass ved bruk av lavnivaas-, hoeynivaas- og absorpsjonskjoeling sykulser.
NO975691L (no) Næringspreparat mot höyt vanninnhold for fjærkre og andre dyr
NO974480L (no) Anvendelse av vitamin D2 eller vitamin D4 derivater til fremstilling av et medikament for behandling av sekundær hyperparathyreoidisme
MY131298A (en) 5-heteroyl indole derivatives
ES2126122T3 (es) Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio.
FI940383A0 (fi) Menetelmä ja laite H2-ilma-höyryseoksen sisältämän vedyn rekombinaatiota ja/tai sytyttämistä varten erityisesti ydinvoimalaitosten käyttöön
SG43104A1 (en) Composition and method for scavenging oxygen
DK193585A (da) Kit til brug ved behandling og forebyggelse af osteoporosis
DE69433092D1 (de) Getränk mit einem gehalt an alpha-ketoglutarsäure
IL104082A (en) Wood substitute based on lignocellulosic and inorganic materials method for obtaining the same and use
PL340561A1 (en) Application of a combination of a converting enzyme inhibitor and a diuretic in treating microcirculatory disorders
DK548986D0 (da) Praeparat til behandling af acne vulgaris og fremgangsmaade til dets fremstilling og anvendelse
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
DK0736033T3 (da) Hidtil ukendte terapeutiske carbohydratblandinger, som er nyttige til afhjælpning af præmenstruelt syndrom
DE69638106D1 (de) Regulation von Körpergewicht durch Materialien basierend auf Zitrusvariationen
ES8705068A1 (es) Estructura perfeccionada para plataformas petroliferas mari-nas
BR0116128A (pt) Processo para inertizar uma cinza proveniente da incineração de rejeitos urbanos e pozolana artificial
ES2099865T3 (es) Ciclopentanoperhidrofenantreno-17beta-(3-furil)-3-derivados y composiciones farmaceuticas que comprenden los mismos para el tratamiento de trastornos cardiovasculares.
FI945328A7 (fi) Laitos sähköenergian tuottamiseksi polttoaineista, erityisesti biogeenisistä polttoaineista
FI954896A7 (fi) Menetelmä ja laite bioaineiden, erityisesti hakkeen polttamiseksi hiilipölylämmitetyssä höyrykattilassa tai pyörrekerrospolttolaitoksessa